Literature DB >> 8851509

In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue.

P Barbe1, L Millet, J Galitzky, M Lafontan, M Berlan.   

Abstract

1. The involvement of beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow was investigated in abdominal subcutaneous adipose tissue of healthy young adults by use of an in situ microdialysis technique. 2. Dialysis probes were infused either with isoprenaline (non-selective beta-adrenoceptor agonist), CGP 12,177 (selective beta 3-adrenoceptor agonist having beta 1-/beta 2-antagonist properties), dobutamine (selective beta 1-adrenoceptor agonist) or terbutaline (selective beta 2-adrenoceptor agonist). The recovery of each probe used for perfusion was calculated by an in vivo calibration method. The local blood flow was estimated through the measurement of the escape of ethanol infused simultaneously with the drugs included in the probe. 3. Isoprenaline infusion at 0.01 microM had a weak effect while higher concentrations of isoprenaline (0.1 and 1 microM) caused a rapid, sustained and concentration-dependent increase of glycerol outflow; the maximum increase was 306 +/- 34% with 1 microM. Isoprenaline also increased the nutritive blood flow in adipose tissue; a significant effect appeared at 0.1 microM isoprenaline and was greater at 1 microM. 4. CGP 12,177 (10 and 100 microM) increased the glycerol concentration in the dialysate (128 +/- 8 and 149 +/- 12%, respectively) and nutritive blood flow. Terbutaline and dobutamine (100 microM) both provoked rapid and similar increases in glycerol outflow (252 +/- 18 and 249 +/- 18%, respectively). Both, terbutaline and dobutamine increased nutritive blood flow. 5. It is concluded that beta 1- and beta 2-adrenoceptor subtypes are both mainly involved in the mobilization of lipids and in the control of nutritive blood flow. beta 3-Adrenoceptors play a weaker role in the control of lipolysis and nutritive blood flow in human subcutaneous abdominal adipose tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851509      PMCID: PMC1909425          DOI: 10.1111/j.1476-5381.1996.tb15279.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

Review 1.  Is the adipocyte beta-adrenoceptor a prototype for the recently cloned atypical 'beta 3-adrenoceptor'?

Authors:  J Zaagsma; S R Nahorski
Journal:  Trends Pharmacol Sci       Date:  1990-01       Impact factor: 14.819

2.  The beta-adrenergic radioligand [3H]CGP-12177, generally classified as an antagonist, is a thermogenic agonist in brown adipose tissue.

Authors:  N Mohell; A Dicker
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

Review 3.  Blood circulation in adipose tissue.

Authors:  S Rosell; E Belfrage
Journal:  Physiol Rev       Date:  1979-10       Impact factor: 37.312

4.  A microdialysis method allowing characterization of intercellular water space in humans.

Authors:  P Lönnroth; P A Jansson; U Smith
Journal:  Am J Physiol       Date:  1987-08

5.  Characterization by microdialysis of intracellular glucose level in subcutaneous tissue in humans.

Authors:  P A Jansson; J Fowelin; U Smith; P Lönnroth
Journal:  Am J Physiol       Date:  1988-08

6.  Radiometric assays for glycerol, glucose, and glycogen.

Authors:  D C Bradley; H R Kaslow
Journal:  Anal Biochem       Date:  1989-07       Impact factor: 3.365

7.  Differentiation of receptor systems activated by sympathomimetic amines.

Authors:  A M Lands; A Arnold; J P McAuliff; F P Luduena; T G Brown
Journal:  Nature       Date:  1967-05-06       Impact factor: 49.962

8.  Microdialysis of adipose tissue and blood for in vivo lipolysis studies.

Authors:  P Arner; J Bolinder; A Eliasson; A Lundin; U Ungerstedt
Journal:  Am J Physiol       Date:  1988-11

9.  Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.

Authors:  J V Durnin; J Womersley
Journal:  Br J Nutr       Date:  1974-07       Impact factor: 3.718

10.  Discrepancies in lipolytic activities induced by beta-adrenoceptor agonists in human and rat adipocytes.

Authors:  C Hollenga; M Haas; J T Deinum; J Zaagsma
Journal:  Horm Metab Res       Date:  1990-01       Impact factor: 2.936

View more
  29 in total

1.  Association of β-2 adrenergic agonist and corticosteroid injection in the treatment of lipomas.

Authors:  L M Redman; C Moro; J Dobak; Y Yu; T S Guillot; F L Greenway
Journal:  Diabetes Obes Metab       Date:  2011-06       Impact factor: 6.577

2.  The Trp64Arg mutation of the beta3 adrenergic receptor gene has no effect on obesity phenotypes in the Québec Family Study and Swedish Obese Subjects cohorts.

Authors:  J Gagnon; P Mauriège; S Roy; D Sjöström; Y C Chagnon; F T Dionne; J M Oppert; L Pérusse; L Sjöström; C Bouchard
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Environmental factors and beta2-adrenergic receptor polymorphism: influence on the energy expenditure and nutritional status of obese women.

Authors:  Eliane Lopes Rosado; Josefina Bressan; J Alfredo Martínez
Journal:  Lipids       Date:  2015-04-18       Impact factor: 1.880

4.  Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies.

Authors:  Hao Lou; Michael J Hageman
Journal:  Pharm Res       Date:  2021-03-12       Impact factor: 4.200

Review 5.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

6.  Down-regulation of beta3-adrenergic receptor expression in rat adipose tissue during the fasted/fed transition: evidence for a role of insulin.

Authors:  K E Hadri; C Charon; J Pairault; S Hauguel-De Mouzon; A Quignard-Boulangé; B Fève
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

Review 7.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

8.  PDE3 and PDE4 isozyme-selective inhibitors are both required for synergistic activation of brown adipose tissue.

Authors:  Stephen M Kraynik; Robert S Miyaoka; Joseph A Beavo
Journal:  Mol Pharmacol       Date:  2013-03-14       Impact factor: 4.436

Review 9.  Catecholamines and obesity: effects of exercise and training.

Authors:  Hassane Zouhal; Sophie Lemoine-Morel; Marie-Eve Mathieu; Gretchen A Casazza; Georges Jabbour
Journal:  Sports Med       Date:  2013-07       Impact factor: 11.136

Review 10.  The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Authors:  Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.